[go: up one dir, main page]

AR127966A1 - Formulaciones tópicas de inhibidores de pi3k-delta - Google Patents

Formulaciones tópicas de inhibidores de pi3k-delta

Info

Publication number
AR127966A1
AR127966A1 ARP220103435A ARP220103435A AR127966A1 AR 127966 A1 AR127966 A1 AR 127966A1 AR P220103435 A ARP220103435 A AR P220103435A AR P220103435 A ARP220103435 A AR P220103435A AR 127966 A1 AR127966 A1 AR 127966A1
Authority
AR
Argentina
Prior art keywords
pi3k
topical formulations
delta inhibitors
skin
pharmaceutically acceptable
Prior art date
Application number
ARP220103435A
Other languages
English (en)
Inventor
Indushekhar Persaud
Melissa Parker
Paul Smith
Zheng Zhang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR127966A1 publication Critical patent/AR127966A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica, adecuada para la aplicación tópica en la piel de un paciente humano con un trastorno de la piel, caracterizada porque comprende: (1) una cantidad terapéuticamente eficaz de un agente terapéutico que es (R)-4-(3-((S)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil)-5-cloro-2-etoxi-6-fluorofenil)pirrolidin-2-ona, o una sal farmacéuticamente aceptable de este; y (2) un medio para efectuar la penetración en la piel del agente terapéutico o una sal farmacéuticamente aceptable de este para el paciente.
ARP220103435A 2021-12-16 2022-12-15 Formulaciones tópicas de inhibidores de pi3k-delta AR127966A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163290518P 2021-12-16 2021-12-16

Publications (1)

Publication Number Publication Date
AR127966A1 true AR127966A1 (es) 2024-03-13

Family

ID=85172615

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103435A AR127966A1 (es) 2021-12-16 2022-12-15 Formulaciones tópicas de inhibidores de pi3k-delta

Country Status (4)

Country Link
US (1) US20230190755A1 (es)
AR (1) AR127966A1 (es)
TW (1) TW202329976A (es)
WO (1) WO2023114369A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087760A1 (es) 2011-09-02 2014-04-16 Incyte Corp Heterociclilaminas como inhibidores de pi3k
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
AR087760A1 (es) 2011-09-02 2014-04-16 Incyte Corp Heterociclilaminas como inhibidores de pi3k
TW202214254A (zh) 2013-03-01 2022-04-16 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
EA202191009A1 (ru) 2014-04-08 2021-08-31 Инсайт Корпорейшн Лечение b-клеточных злокачественных новообразований с применением комбинации ингибиторов jak и pi3k
US20170158699A1 (en) * 2014-05-27 2017-06-08 Almirall, S.A. Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile
PT3831833T (pt) * 2015-02-27 2023-02-06 Incyte Corp Processos para a preparação de um inibidor pi3k
KR102884803B1 (ko) 2018-06-01 2025-11-12 인사이트 코포레이션 Pi3k 관련 장애의 치료를 위한 투여 요법

Also Published As

Publication number Publication date
WO2023114369A3 (en) 2023-08-10
US20230190755A1 (en) 2023-06-22
TW202329976A (zh) 2023-08-01
WO2023114369A2 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
SA521421897B1 (ar) تركيبة تعتمد على جزء من نباتات طبية أو مستخلصاتها واستخداماتها ومنتجاتها
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
MX2019012884A (es) Terapia de combinacion.
AR002262A1 (es) Composicion y metodo para el tratamiento de enfermedades fungales de las unas y un vendaje adaptado para la administracion topica de medicacion a lasunas.
BR112020019875A8 (pt) composições tópicas para alívio da dor
AR127966A1 (es) Formulaciones tópicas de inhibidores de pi3k-delta
CL2009002183A1 (es) Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica.
BR112015030578A2 (pt) combinações farmacêuticas
CO5590913A2 (es) Terapia de combinacion antivirica
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
BRPI0807940B8 (pt) usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2023003783A (es) Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.
WO2020170030A3 (en) Method for providing early onset of action in the treatment of rosacea
MX2021003030A (es) Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
RU2005131578A (ru) Аплидин для лечения множественной миеломы
AR111699A1 (es) Composición farmacéutica que comprende betahistina
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2
CO5011042A1 (es) Uso de una oxazolidinona para la fabricacion de un medicamento para administracion topica
WO2023019095A3 (en) Momelotinib combination therapy
EA202000298A1 (ru) ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ
PH12022553502A1 (en) Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine
BR112016012141A2 (pt) "combinações farmacêuticas, uso das mesmas, e embalagem comercial"

Legal Events

Date Code Title Description
FB Suspension of granting procedure